Evidence map›Paper›PMID 38245015›Full record

ArticleBMJ open2024

Thoracentesis to alleviate pleural effusion in acute heart failure: study protocol for the multicentre, open-label, randomised controlled TAP-IT trial.

Signe Glargaard, Jakob Hartvig Thomsen, Brian Bridal Løgstrup, Morten Schou, Kasper Karmark Iversen, Christian Tuxen, Olav W Nielsen, Christian Axel Bang, Matias Greve Lindholm, Ekim Seven and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05017753 (Thoracentesis to Alleviate Cardiac Pleural Effusion - an Interventional Trial), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05017753 nacompletednot on this map

Thoracentesis to Alleviate Cardiac Pleural Effusion - an Interventional Trial (TAP-IT)

TypeinterventionalSponsorBispebjerg HospitalRan2021 to 2024Enrolled135ConditionsHeart Failure, Pleural EffusionArmsThoracentesis, Standard-of-care medical treatment
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Signe GlargaardDepartment of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark signe.glargaard@regionh.dk.ORCID 0000-0002-7113-5055
Jakob Hartvig ThomsenDepartment of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Brian Bridal LøgstrupDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Morten SchouDepartment of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
Kasper Karmark IversenDepartment of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
Christian TuxenDepartment of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Olav W NielsenDepartment of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Christian Axel BangDepartment of Cardiology, Zealand University Hospital Roskilde, Roskilde, Denmark.
Matias Greve LindholmDepartment of Cardiology, Zealand University Hospital Roskilde, Roskilde, Denmark.
Ekim SevenDepartment of Cardiology, Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, Denmark.
Anders BarasaDepartment of Cardiology, Copenhagen University Hospital-Glostrup, Glostrup, Denmark.
Nis StrideDepartment of Cardiology, Copenhagen University Hospital-North Zealand, Hilleroed, Denmark.
Søren VraaDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Marlene TofterupDepartment of Cardiology, Odense University Hospital, Odense, Denmark.
Rasmus Vedby RasmussenDepartment of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
Dan Eik HøfstenDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Kasper RossingDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Lars KøberDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Finn GustafssonDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jens Jakob ThuneDepartment of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
University of Copenhagen · DKFrederiksberg Hospital · DKZealand University Hospital · DKAalborg University Hospital · DKAarhus University · DKAmager Hospital · DKCopenhagen University Hospital · DKGentofte Hospital · DKGlostrup Hospital · DKOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPleural effusion is present in half of the patients hospitalised with acute heart failure. The condition is treated with diuretics and/or therapeutic thoracentesis for larger effusions. No evidence from randomised trials or guidelines supports thoracentesis to alleviate pleural effusion due to acute heart failure. The Thoracentesis to Alleviate cardiac Pleural effusion Interventional Trial (TAP-IT) will investigate if a strategy of referring patients with acute heart failure and pleural effusion to up-front thoracentesis by pleural pigtail catheter insertion in addition to pharmacological therapy compared with pharmacological therapy alone can increase the number of days the participants are alive and not hospitalised during the 90 days following randomisation. METHODS AND ANALYSIS: TAP-IT is a pragmatic, multicentre, open-label, randomised controlled trial aiming to include 126 adult patients with left ventricular ejection fraction ≤45% and a non-negligible pleural effusion due to heart failure. Participants will be randomised 1:1, stratified according to site and anticoagulant treatment, and assigned to referral to up-front ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard pharmacological therapy or to standard pharmacological therapy only. Thoracentesis is performed according to local guidelines and can be performed in participants in the pharmacological treatment arm if their condition deteriorates or if no significant improvement is observed within 5 days. The primary endpoint is how many days participants are alive and not hospitalised within 90 days from randomisation and will be analysed in the intention-to-treat population. Key secondary outcomes include 90-day mortality, complications, readmissions, and quality of life. ETHICS AND DISSEMINATION: The study has been approved by the Capital Region of Denmark Scientific Ethical Committee (H-20060817) and Knowledge Center for Data Reviews (P-2021-149). All participants will sign an informed consent form. Enrolment began in August 2021. Regardless of the nature, results will be published in a peer-reviewed medical journal. TRIAL REGISTRATION NUMBER: NCT05017753.

Indexed as

Heart FailurePleural EffusionAdultHumansMulticenter Studies as TopicPragmatic Clinical Trials as TopicQuality of LifeRandomized Controlled Trials as TopicStroke VolumeThoracentesisVentricular Function, LeftCardiologyClinical TrialHeart failure

Identifiers

PMID38245015
PMCPMC10806591
OpenAlexW4391053857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.